A newer version of this project is available. See below for other available versions.

Replication package: A closer look at Doleac and Mukherjee (2022) and the effects of naloxone access laws on opioid ER admissions

Principal Investigator(s):  View help for Principal Investigator(s) Sergey Alexeev

Version:  View help for Version V1

Version Title:  View help for Version Title First (prepublication) upload

Name File Type Size Last Modified
Crime_Data.dta application/x-stata-dta 18.7 MB 11/15/2024 05:35:PM
DM replication.do text/plain 42.7 KB 11/15/2024 05:09:PM
DownloadTable_Opioids_2023-06.xlsx application/vnd.openxmlformats-officedocument.spreadsheetml.sheet 2.2 MB 11/14/2024 02:37:PM
DownloadTable_StatePayerED_11-23-22.xls application/vnd.ms-excel 1.8 MB 11/14/2024 02:03:PM
Google_MET.dta application/x-stata-dta 1.8 MB 11/14/2024 02:03:PM
HCUP_Data.dta application/x-stata-dta 98.3 KB 11/14/2024 02:35:PM
README.docx application/vnd.openxmlformats-officedocument.wordprocessingml.document 21.1 KB 11/15/2024 03:38:PM
README.pdf application/pdf 123.5 KB 11/15/2024 03:42:PM

Project Citation: 

Alexeev, Sergey. Replication package: A closer look at Doleac and Mukherjee (2022) and the effects of naloxone access laws on opioid ER admissions. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2024-11-15. https://doi.org/10.3886/E211161V1

Project Description

Summary:  View help for Summary
The replication materials provided here are associated with the study with the following abstract:

Doleac and Mukherjee (2022) conclude that broadening access to a life-saving drug – naloxone – does not reduce opioid-related mortality as the drug simultaneously encourages riskier drug use. I show issues with their data, design, and estimation methods. For example, their Google Search data never existed, the law timing is incorrect, and the statistical inference is invalid. Correcting these issues within a triple difference design shows that naloxone, contrary to their findings, does not increase ER opioid admissions. I conclude that the moral hazard (and the ensuing adverse consequences) of naloxone use lacks empirical support.


Scope of Project

Subject Terms:  View help for Subject Terms Naloxone; Public health; Opioids; Moral hazard; Replication
JEL Classification:  View help for JEL Classification
      C31 Multiple or Simultaneous Equation Models: Cross-Sectional Models; Spatial Models; Treatment Effect Models; Quantile Regressions; Social Interaction Models
      H51 National Government Expenditures and Health
      I12 Health Behavior
      I18 Health: Government Policy; Regulation; Public Health
      K32 Energy, Environmental, Health, and Safety Law
Manuscript Number:  View help for Manuscript Number ECIN-Jan-2024-0045.R1
Geographic Coverage:  View help for Geographic Coverage United States
Time Period(s):  View help for Time Period(s) 2005 – 2018

Methodology

Data Source:  View help for Data Source
  1. Healthcare Cost and Utilization Project (HCUP). 2024a. “Quarterly and Annual Rates for Opioid-Related Hospital Use.” Link
  2. Healthcare Cost and Utilization Project (HCUP). 2024b. “State Trends in Emergency Department Visits by Payer.” Link
  3. Doleac, Jennifer L., and Anita Mukherjee. 2022. “The Effects of Naloxone Access Laws on Opioid Abuse, Mortality, and Crime.” The Journal of Law and Economics 65 (2): 211–238. Supplementary data: Link

Related Publications

Download this project

Published Versions

V5 [2025-01-15]

V4 [2025-01-13]

V3 [2025-01-10]

V2 [2024-11-19]

V1 [2024-11-15]

Export Metadata

Dublin Core

DDI 2.5

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.